Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
American Journal of Cardiovascular Drugs
Published in: American Journal of Cardiovascular Drugs 1/2024

17-11-2023 | Empagliflozin | Systematic Review

The Use of Sodium-Glucose Cotransporter-2 Inhibitors in Coronary Revascularization: Where Are We Now? A Systematic Review

Authors: Ryaan EL-Andari, Nicholas M. Fialka, Jimmy Kang, Sabin J. Bozso, Jayan Nagendran, Jeevan Nagendran

Published in: American Journal of Cardiovascular Drugs | Issue 1/2024

Login to get access

Abstract

Introduction

Diabetes and coronary artery disease are two common conditions that often co-exist. In recent years, sodium-glucose cotransporter 2 inhibitors (SGLT2i) have been demonstrated to provide significant cardioprotective benefits, especially among patients with heart failure.

Objective

In this systematic review, we look to identify the outcomes SGLT2i use in patients undergoing coronary revascularization.

Methods

Pubmed and Embase were systematically searched for articles describing the outcomes of patients taking SGLT2i and undergoing coronary revascularization. 834 titles and abstracts were screened, 42 full texts were reviewed, and 18 studies were found to meet the inclusion criteria and were included in this review.

Results

For patients undergoing coronary artery bypass grafting and percutaneous coronary intervention, the use of SGLT2i resulted in reductions in mortality, hospitalization for heart failure, and improved blood glucose; however, these benefits were not consistently reported in the literature. Reduced inflammatory markers and positive cardiac remodeling were identified among patients taking SGLT2i.

Conclusions

Sodium-glucose cotransporter 2 inhibitors (SGLT2i) have been demonstrated to provide benefits for patients with heart failure along with a host of positive modulatory effects on the cardiovascular system, including reductions in inflammatory properties, hypertension, and left ventricular volume load. Given the clear benefit provided by SGLT2i to patients with cardiovascular disease and a host of positive properties that are expected to be protective for patients with ischemic heart disease, future investigation into the relationship between SGLT2i and outcomes for patients undergoing revascularization is imperative.
Appendix
Available only for authorised users
Literature
1.
Htay T, Soe K, Lopez-Perez A, Doan AH, Romagosa MA, Aung K. Mortality and cardiovascular disease in type 1 and type 2 diabetes. Curr Cardiol Rep. 2019;21:1–7.CrossRef
2.
Navaratnarajah M, Rea R, Evans R, Gibson F, Antoniades C, Keiralla A, et al. Effect of glycaemic control on complications following cardiac surgery: literature review. J Cardiothorac Surg. 2018;13:10.PubMedPubMedCentralCrossRef
3.
Halkos ME, Puskas JD, Lattouf OM, Kilgo P, Kerendi F, Song HK, et al. Elevated preoperative hemoglobin A1c level is predictive of adverse events after coronary artery bypass surgery. J Thorac Cardiovasc Surg. 2008;136:631–40.PubMedCrossRef
4.
Henning RJ. Type-2 diabetes mellitus and cardiovascular disease. Future Cardiol. 2018;14:491–509.PubMedCrossRef
5.
6.
Stone JA, Houlden RL, Lin P, Udell JA, Verma S. Cardiovascular protection in people with diabetes. Can J Diabetes. 2018;42:S162–9.PubMedCrossRef
7.
Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020;41:255–323.PubMedCrossRef
8.
O’Meara E, McDonald M, Chan M, Ducharme A, Ezekowitz JA, Giannetti N, et al. CCS/CHFS heart failure guidelines: clinical trial update on functional mitral regurgitation, SGLT2 Inhibitors, ARNI in HFpEF, and Tafamidis in Amyloidosis. Can J Cardiol. 2020;36:159–69.PubMedCrossRef
9.
Thourani VH, Weintraub WS, Stein B, Gebhart SSP, Craver JM, Jones EL, et al. Influence of diabetes mellitus on early and late outcome after coronary artery bypass grafting. Ann Thorac Surg. 1999;67:1045.PubMedCrossRef
10.
Carson JL, Scholz PM, Chen AY, Peterson ED, Gold J, Schneider SH. Diabetes mellitus increases short-term mortality and morbidity in patients undergoing coronary artery bypass graft surgery. J Am Coll Cardiol. 2002;40:418–23.PubMedCrossRef
11.
Woods SE, Smith JM, Sohail S, Sarah A, Engle A. The influence of type 2 diabetes mellitus in patients undergoing coronary artery bypass graft surgery: an 8-year prospective cohort study. Chest. 2004;126:1789–95.PubMedCrossRef
12.
Cardona S, Pasquel FJ, Fayfman M, Peng L, Jacobs S, Vellanki P, et al. Hospitalization costs and clinical outcomes in CABG patients treated with intensive insulin therapy. J Diabetes Complications. 2017;31:742–7.PubMedCrossRef
13.
ADVANCE Collaborative Group; Patel A, MacMahon S, Chalmers J, Neal B, Billot L, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Eng J Med 2008;358:2560–72.
14.
Skyler JS, Bergenstal R, Bonow RO, Buse J, Deedwania P, Gale EAM, et al. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA Diabetes Trials. Diabetes Care. 2009;32:187–92.PubMedPubMedCentralCrossRef
15.
Turnbull FM, Abraira C, Anderson RJ, Byington RP, Chalmers JP, Duckworth WC, et al. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia. 2009;52:2288–98.PubMedCrossRef
16.
Liosis S, Hochadel M, Darius H, Behrens S, Mudra H, Lauer B, et al. Effect of renal insufficiency and diabetes mellitus on in-hospital mortality after acute coronary syndromes treated with primary PCI. Results from the ALKK PCI Registry. Int J Cardiol. 2019;292:43–9.PubMedCrossRef
17.
Karayiannides S, Norhammar A, Frøbert O, James SK, Lagerqvist B, Lundman P. Prognosis in patients with diabetes mellitus and STEMI undergoing primary PCI. J Am Coll Cardiol. 2018;72:1427–8.PubMedCrossRef
18.
Cannon CP, Perkovic V, Agarwal R, Baldassarre J, Bakris G, Charytan DM, et al. Evaluating the effects of canagliflozin on cardiovascular and renal events in patients with type 2 diabetes mellitus and chronic kidney disease according to baseline HbA1c, Including Those With HbA1c <7%: Results From the CREDENCE Trial. Circulation. 2020;141:407–10.PubMedCrossRef
19.
Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Eng J Med. 2020;383:1413–24.CrossRef
20.
Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Böhm M, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Eng J Med. 2021;385:1451–61.CrossRef
21.
Ferrannini E, Mark M, Mayoux E. CV Protection in the EMPA-REG OUTCOME Trial: A “Thrifty Substrate” Hypothesis. Diabetes Care. 2016;39:1108–14.PubMedCrossRef
22.
Fitchett D, Zinman B, Wanner C, Lachin JM, Hantel S, Salsali A, et al. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial. Eur Heart J. 2016;37:1526–34.PubMedPubMedCentralCrossRef
23.
Verma S, Mazer CD, Fitchett D, Inzucchi SE, Pfarr E, George JT, et al. Empagliflozin reduces cardiovascular events, mortality and renal events in participants with type 2 diabetes after coronary artery bypass graft surgery: subanalysis of the EMPA-REG OUTCOME® randomised trial. Diabetologia. 2018;61:1712–23.PubMedPubMedCentralCrossRef
24.
Perkovic V, de Zeeuw D, Mahaffey KW, Fulcher G, Erondu N, Shaw W, et al. Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials. Lancet Diabetes Endocrinol. 2018;6:691–704.PubMedCrossRef
25.
Solomon SD, McMurray JJV, Claggett B, de Boer RA, DeMets D, Hernandez AF, et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Eng J Med. 2022;387:1089–98.CrossRef
26.
Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Eng J Med. 2017;377:644–57.CrossRef
27.
Olsen MB, Gregersen I, Sandanger Ø, Yang K, Sokolova M, Halvorsen BE, et al. Targeting the inflammasome in cardiovascular disease. JACC Basic Transl Sci. 2022;7:84–98.PubMedCrossRef
28.
Paolisso P, Foà A, Bergamaschi L, Donati F, Fabrizio M, Chiti C, et al. Hyperglycemia, inflammatory response and infarct size in obstructive acute myocardial infarction and MINOCA. Cardiovasc Diabetol. 2021;20(1):33.PubMedPubMedCentralCrossRef
29.
Paolisso P, Bergamaschi L, Santulli G, Gallinoro E, Cesaro A, Gragnano F, et al. Infarct size, inflammatory burden, and admission hyperglycemia in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors: a multicenter international registry. Cardiovasc Diabetol. 2022;21:1–12.CrossRef
30.
Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535–b2535.PubMedPubMedCentralCrossRef
31.
Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JPA, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009;339:b2700–b2700.PubMedPubMedCentralCrossRef
32.
Sardu C, Massetti M, Testa N, di Martino L, Castellano G, Turriziani F, et al. Effects of Sodium-Glucose Transporter 2 Inhibitors (SGLT2-I) in Patients With Ischemic Heart Disease (IHD) Treated by Coronary Artery Bypass Grafting via MiECC: Inflammatory Burden, and Clinical Outcomes at 5 Years of Follow-Up. Front Pharmacol. 2021;12:1–10.CrossRef
33.
Lee SJ, Lee KH, Oh HG, Seo HJ, Jeong SJ, Kim CH. Effect of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase 4 inhibitors on cardiovascular function in patients with type 2 diabetes mellitus and coronary artery disease. J Obes Metab Syndr. 2019;28:254–61.PubMedPubMedCentralCrossRef
34.
Lee H-F, Chan Y-H, Chuang C, Li P-R, Yeh Y-H, Hsiao F-C, et al. Cardiovascular, renal, and lower limb outcomes in patients with type 2 diabetes after percutaneous coronary intervention and treated with sodium–glucose cotransporter 2 inhibitors vs. dipeptidyl peptidase-4 inhibitors. Eur Heart J Cardiovasc Pharmacother. 2023;9:301–10.PubMedCrossRef
35.
Paolisso P, Bergamaschi L, Gragnano F, Gallinoro E, Cesaro A, Sardu C, et al. Outcomes in diabetic patients treated with SGLT2-Inhibitors with acute myocardial infarction undergoing PCI: the SGLT2-I AMI PROTECT Registry. Pharmacol Res. 2023;187: 106597.PubMedCrossRef
36.
Lin Y, Zhou F, Wang X, Guo Y, Chen W. Effect of dapagliflozin on clinical outcome after drug-eluting stent implantation in elderly T2DM patients: a real-world study. Comput Math Methods Med. 2023;2023:1–5.CrossRef
37.
Marfella R, Sardu C, D’Onofrio N, Fumagalli C, Scisciola L, Sasso FC, et al. SGLT-2 inhibitors and in-stent restenosis-related events after acute myocardial infarction: an observational study in patients with type 2 diabetes. BMC Med. 2023;21(1):71.PubMedPubMedCentralCrossRef
38.
Adel SMH, Jorfi F, Mombeini H, Rashidi H, Fazeli S. Effect of a low dose of empagliflozin on short-term outcomes in type 2 diabetics with acute coronary syndrome after percutaneous coronary intervention. Saudi Med J. 2022;43:458–64.PubMedPubMedCentralCrossRef
39.
Feitosa MPM, Lima EG, Abizaid AAC, Mehran R, Lopes NHM, de Assis Fischer Ramos T, et al. The safety of SGLT-2 inhibitors in diabetic patients submitted to elective percutaneous coronary intervention regarding kidney function: SAFE-PCI pilot study. Diabetol Metab Syndr. 2023;15:138.PubMedPubMedCentralCrossRef
40.
Hua R, Ding N, Guo H, Wu Y, Yuan Z, Li T. Contrast-induced acute kidney injury in patients on SGLT2 inhibitors undergoing percutaneous coronary interventions: a propensity-matched analysis. Front Cardiovasc Med. 2022;9:1–9.CrossRef
41.
Khorlampenko AA, Karetnikova VN, Kochergina AM, Ignatova JS, Dyleva JA, Gruzdeva OL. Effect of empagliflosin on renal filtration in patients with coronary heart disease undergoing percutaneous coronary intervention [in Russian]. Kardiologiya. 2020;60:63–8.CrossRef
42.
von Lewinski D, Kolesnik E, Tripolt NJ, Pferschy PN, Benedikt M, Wallner M, et al. Empagliflozin in acute myocardial infarction: the EMMY trial. Eur Heart J. 2022;43:4421–32.CrossRef
43.
Zhu Y, Zhang J, Yan X, Sun L, Ji Y, Wang F. Effect of dapagliflozin on the prognosis of patients with acute myocardial infarction undergoing percutaneous coronary intervention. Cardiovasc Diabetol. 2022;21:1–10.CrossRef
44.
Hashikata T, Ikutomi M, Jimba T, Shindo A, Kakuda N, Katsushika S, et al. Empagliflozin attenuates neointimal hyperplasia after drug-eluting-stent implantation in patients with type 2 diabetes. Heart Vessels. 2020;35:1378–89.PubMedCrossRef
45.
Dayem KA, Younis O, Zarif B, Attia S, AbdelSalam A. Impact of dapagliflozin on cardiac function following anterior myocardial infarction in non-diabetic patients—DACAMI (a randomized controlled clinical trial). Int J Cardiol. 2023;379:9–14.PubMedCrossRef
46.
47.
Benedikt M, Mangge H, Aziz F, Curcic P, Pailer S, Herrmann M, et al. Impact of the SGLT2-inhibitor empagliflozin on inflammatory biomarkers after acute myocardial infarction – a post-hoc analysis of the EMMY trial. Cardiovasc Diabetol. 2023;22:166.PubMedPubMedCentralCrossRef
48.
McDonald M, Virani S, Chan M, Ducharme A, Ezekowitz JA, Giannetti N, et al. CCS/CHFS heart failure guidelines update: defining a new pharmacologic standard of care for heart failure with reduced ejection fraction. Can J Cardiol. 2021;37:531–46.PubMedCrossRef
49.
Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. 2022 AHA/ACC/hfsa guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145:E895-1032.PubMed
50.
Sardu C, Trotta MC, Sasso FC, Sacra C, Carpinella G, Mauro C, et al. SGLT2-inhibitors effects on the coronary fibrous cap thickness and MACEs in diabetic patients with inducible myocardial ischemia and multi vessels non-obstructive coronary artery stenosis. Cardiovasc Diabetol. 2023;22:80.PubMedPubMedCentralCrossRef
51.
Gager GM, von Lewinski D, Sourij H, Jilma B, Eyileten C, Filipiak K, et al. Effects of SGLT2 Inhibitors on Ion Homeostasis and Oxidative Stress associated Mechanisms in Heart Failure. Biomed Pharmacother. 2021;143: 112169.PubMedCrossRef
52.
D’Onofrio N, Sardu C, Trotta MC, Scisciola L, Turriziani F, Ferraraccio F, et al. Sodium-glucose co-transporter2 expression and inflammatory activity in diabetic atherosclerotic plaques: effects of sodium-glucose co-transporter2 inhibitor treatment. Mol Metab. 2021;54: 101337.PubMedPubMedCentralCrossRef
53.
Salvatore T, Caturano A, Galiero R, di Martino A, Albanese G, Vetrano E, et al. Cardiovascular benefits from gliflozins: effects on endothelial function. Biomedicines. 2021;9:1356.PubMedPubMedCentralCrossRef
54.
Paolisso P, Bergamaschi L, Cesaro A, Gallinoro E, Gragnano F, Sardu C, et al. Impact of SGLT2-inhibitors on contrast-induced acute kidney injury in diabetic patients with acute myocardial infarction with and without chronic kidney disease: Insight from SGLT2-I AMI PROTECT registry. Diabetes Res Clin Pract. 2023;202: 110766.PubMedCrossRef
Metadata
Title
The Use of Sodium-Glucose Cotransporter-2 Inhibitors in Coronary Revascularization: Where Are We Now? A Systematic Review
Authors
Ryaan EL-Andari
Nicholas M. Fialka
Jimmy Kang
Sabin J. Bozso
Jayan Nagendran
Jeevan Nagendran
Publication date
17-11-2023
Publisher
Springer International Publishing
Published in
American Journal of Cardiovascular Drugs / Issue 1/2024
Print ISSN: 1175-3277
Electronic ISSN: 1179-187X
DOI
https://doi.org/10.1007/s40256-023-00618-0

Other articles of this Issue 1/2024

American Journal of Cardiovascular Drugs 1/2024 Go to the issue

Original Research Article

Rivaroxaban Plasma Concentration and Clinical Outcomes on Older Patients with Non-valvular Atrial Fibrillation and Pulmonary Infection

Original Research Article

The Cost-Effectiveness of Rivaroxaban Plus Aspirin Compared with Aspirin Alone in the COMPASS Trial: A US Perspective

Systematic Review

Intravenous Diltiazem Versus Metoprolol in Acute Rate Control of Atrial Fibrillation/Flutter and Rapid Ventricular Response: A Meta-Analysis of Randomized and Observational Studies

Systematic Review

Safety and Efficacy of Cangrelor in Acute Coronary Syndromes: A Systematic Review and Network Meta-Analysis

Systematic Review

Safety and Efficacy of Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors After Acute Coronary Syndrome: A Meta-analysis of Randomized Controlled Trials

Review Article

Iron dyshomeostasis and mitochondrial function in heart failure